Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
Rhea-AI Summary
Hemogenyx Pharmaceuticals (LSE:HEMO) has announced the recruitment of its second patient for the clinical trial of HG-CT-1, their proprietary CAR-T cell therapy. The trial focuses on treating relapsed or refractory acute myeloid leukemia (R/R AML) in adult patients.
The company's scientific team will soon begin manufacturing HG-CT-1 for the second patient. This development represents a significant milestone in advancing a potential breakthrough treatment for AML patients with therapeutic options.
The recruitment progress suggests promising initial trial results, demonstrating the company's commitment to addressing urgent unmet medical needs in blood disease treatment.
Positive
- Clinical trial progression with second patient recruitment indicates positive development momentum
- Manufacturing capabilities ready for immediate HG-CT-1 production for second patient
Negative
- Early clinical trial stage with only two patients recruited indicates long path to potential commercialization
Recruitment of Second Patient for HG-CT-1 Clinical Trial
LONDON, GB / ACCESS Newswire / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant step forward in the Company's clinical development program and underscores the progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.
The manufacturing of HG-CT-1 for the second patient, carried out by the Company's team of scientists and quality control professionals, is scheduled to commence shortly.
Further updates on the clinical trial will be provided in due course.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"The recruitment of the second patient is indicative of the promising results of the clinical trial for HG-CT-1 thus far and represents another critical step in advancing HG-CT-1 as a potential breakthrough treatment for relapsed or refractory AML. This milestone reflects the dedication of our team and the strength of our science, bringing us closer to addressing an urgent unmet medical need."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What is the current status of Hemogenyx's HG-CT-1 clinical trial for AML treatment?
What type of treatment is Hemogenyx developing for AML patients?
What stage is Hemogenyx's HG-CT-1 therapy currently in?
What patient population is targeted by Hemogenyx's HG-CT-1 therapy?
